forbesmagazine.uk

Menu
LEADERSHIP

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

Linda
Linda

[ad_1]

Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.

Share This Article
Previous Article Algonquin Power to Sell Renewable Energy Business for $2.5 Billion
Next Article Meta Handed $100 Million Fine in Ireland Over Password Storage
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
- Advertisement -
Ad image

Popular Posts

Saturn Sade Sati, its phases and effects

Sani Sade Sati, or Sade Sati, is a seven-and-a-half-year period of uncertainty and hardship. Saturn…

By Alex

Amazon Shares Slide as Spending Surges and Revenue Outlook Disappoints

The company projected weaker-than-expected revenue growth and said it would continue to ratchet up spending…

By Linda

Walgreens Plans Major U.S. Store Closures; Shares Tumble

Shares of the pharmacy chain plummeted 25% after The Wall Street Journal reported the CEO’s…

By Linda
Lost your password?